Literature DB >> 14562271

Osteogenesis imperfecta--clinical and molecular diversity.

P J Roughley1, F Rauch, F H Glorieux.   

Abstract

Osteogenesis imperfecta is a heritable disorder of bone formation resulting in low bone mass and a propensity to fracture. It exhibits a broad range of clinical severity, ranging from multiple fracturing in utero and perinatal death to normal adult stature and a low fracture incidence. The disorder is currently classified into seven types based on differences in clinical presentation and bone architecture. Mutation in one of the type I collagen genes is commonly associated with osteogenesis imperfecta, but is not a prerequisite for the diagnosis. Indeed, the newer forms of osteogenesis imperfecta (types V, VI and VII) are not associated with type I collagen gene defects. Amongst the type I collagen gene mutations that can occur, missense base substitutions involving glycine codons in the exons encoding the central triple-helix forming domain predominate. Such mutations can occur in all the classical forms of osteogenesis imperfecta (types I-IV), but genotype/phenotype correlations are complex and often unpredictable. Treatment of osteogenesis imperfecta by bisphosphonate therapy can improve bone mass in all types of the disorder, and while not being a cure for the disorder does improve the quality of life of the patient.

Entities:  

Mesh:

Year:  2003        PMID: 14562271     DOI: 10.22203/ecm.v005a04

Source DB:  PubMed          Journal:  Eur Cell Mater        ISSN: 1473-2262            Impact factor:   3.942


  37 in total

1.  mRNA nuclear export and human disease.

Authors:  Jessica A Hurt; Pamela A Silver
Journal:  Dis Model Mech       Date:  2008 Sep-Oct       Impact factor: 5.758

2.  Joint laxity in the parents of children with temporary brittle bone disease.

Authors:  Colin R Paterson; Patricia A Mole
Journal:  Rheumatol Int       Date:  2011-09-01       Impact factor: 2.631

Review 3.  New laboratory tools in the assessment of bone quality.

Authors:  D Chappard; M F Baslé; E Legrand; M Audran
Journal:  Osteoporos Int       Date:  2011-02-24       Impact factor: 4.507

Review 4.  Osteogenesis imperfecta due to mutations in non-collagenous genes: lessons in the biology of bone formation.

Authors:  Joan C Marini; Adi Reich; Simone M Smith
Journal:  Curr Opin Pediatr       Date:  2014-08       Impact factor: 2.856

Review 5.  Diagnosis of Osteoporosis in Children and Adolescents.

Authors:  Christine M Laine; Tero Laine
Journal:  Eur Endocrinol       Date:  2013-08-23

6.  Single molecule effects of osteogenesis imperfecta mutations in tropocollagen protein domains.

Authors:  Alfonso Gautieri; Simone Vesentini; Alberto Redaelli; Markus J Buehler
Journal:  Protein Sci       Date:  2009-01       Impact factor: 6.725

7.  Anesthetic management using total intravenous anesthesia with remifentanil in a child with osteogenesis imperfecta.

Authors:  Satoru Ogawa; Ryu Okutani; Koichi Suehiro
Journal:  J Anesth       Date:  2009-02-22       Impact factor: 2.078

8.  Low Dose of Bisphosphonate Enhances Sclerostin Antibody-Induced Trabecular Bone Mass Gains in Brtl/+ Osteogenesis Imperfecta Mouse Model.

Authors:  Diana Olvera; Rachel Stolzenfeld; Joan C Marini; Michelle S Caird; Kenneth M Kozloff
Journal:  J Bone Miner Res       Date:  2018-05-07       Impact factor: 6.741

9.  Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates.

Authors:  N Nicolaou; Y Agrawal; M Padman; J A Fernandes; M J Bell
Journal:  J Child Orthop       Date:  2012-01-17       Impact factor: 1.548

10.  Two novel COL1A1 mutations in patients with osteogenesis imperfecta (OI) affect the stability of the collagen type I triple-helix.

Authors:  Joanna Witecka; Aleksandra M Auguściak-Duma; Anna Kruczek; Anna Szydło; Marta Lesiak; Maria Krzak; Jacek J Pietrzyk; Minna Männikkö; Aleksander L Sieroń
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.